Pune Ayurvedic Medicine Checks Expose Quality Gaps
Pune’s Ayurvedic medicine manufacturing sector has come under regulatory scrutiny after Maharashtra’s Food and Drug Administration permanently cancelled the manufacturing licence of a Jejuri-based unit following failures in six drug samples. The findings, which included microbial contamination and foreign impurities, raise wider questions about quality controls, traceability and consumer protection in a growing traditional-medicine market. The action against Inducare Pharma Pvt Ltd followed two inspections of its manufacturing facility, according to the state regulator. Officials reported deficiencies ranging from incomplete production documentation to inadequate laboratory systems, sanitation problems and missing pest-control records. The regulator also found gaps between approved formulations and the ingredients used during manufacturing.
Laboratory testing classified six sampled products as Not of Standard Quality, a regulatory term indicating that a medicine fails one or more prescribed quality requirements. Samples of Sinhanad Guggul and Punarnavadi Mandur were reported to have fungal growth, while Hingvastak Churna and Triphala Churna were found with insects, larvae or other foreign material. Triphala Guggul and Kanchanar Guggul exceeded prescribed microbial limits, the regulator said. The findings are also reflected in Maharashtra FDA’s public NSQ database. It lists Inducare products including Triphala Guggul and Kanchanar Guggul for failing microbial-limit testing, while Hingvastak Churna and Triphala Churna appear against other quality parameters. For consumers, the issue extends beyond individual batches. Manufacturing records and distribution data are critical to tracing medicines when complaints or quality failures emerge. The FDA said records for products linked to complaints were unavailable, potentially making it harder to establish where affected batches went and how quickly they could be withdrawn.
The case also highlights a broader infrastructure challenge for regulated manufacturing: compliance depends not only on the final product but on the physical and administrative systems surrounding production. Clean facilities, functioning laboratories, documented processes and reliable supply-chain records form part of the safety architecture that protects patients. Maharashtra FDA identifies enforcement of medicine quality and compliance with the Drugs and Cosmetics Act and related rules among its core responsibilities. Its public database continues to record NSQ products across categories, providing consumers and healthcare professionals with a mechanism to check reported failures.
The immediate regulatory action removes the manufacturing licence, but the larger test will be whether quality failures become easier to detect, trace and communicate before they reach patients. For Maharashtra’s expanding pharmaceutical and traditional-medicine ecosystem, stronger inspection capacity and transparent product traceability remain essential to ensuring growth does not come at the expense of public safety.
